阿片类药物使用障碍
參考文獻

1 2  . U.S. Food and Drug Administration (FDA) (新闻稿). 2016-05-26  [2017-03-16]. （原始内容存档于2017-11-30）.
↑  . . Rockville (MD): Substance Abuse and Mental Health Services Administration (US). 2004  [2022-10-28]. （原始内容存档于2017-02-19）.
1 2 3  . www.cdc.gov. 2017-08-29  [2018-07-16]. （原始内容存档于2019-12-10）.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25  American Psychiatric Association, , Arlington: American Psychiatric Publishing: 540–546, 2013, ISBN 978-0890425558
1 2 3 4 5 6 7 8  Substance Use and Mental Health Services Administration. . 2014-09-30  [2022-10-28]. （原始内容存档于2017-03-12）.
1 2 3  . ACOG. August 2017  [2018-07-16]. （原始内容存档于2018-07-16）.
↑  Farahmand, Pantea; Modesto-Lowe, Vania. . The Journal of American Academy Psychiatry and the Law. 2017  [2022-1-29]. （原始内容存档于2023-01-03）.  请检查|access-date=中的日期值 (帮助)
1 2 3 4 5 6 7 8 9 10 11  Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. . BMJ. April 2017, 357: j1550. PMC 5421454 . PMID 28446428. doi:10.1136/bmj.j1550.
1 2  . Substance Abuse and Mental Health Services Administration. October 2014  [2022-10-28]. （原始内容存档于2017-03-12）.
1 2  McDonald R, Strang J. . Addiction. July 2016, 111 (7): 1177–87. PMC 5071734 . PMID 27028542. doi:10.1111/add.13326.
1 2  Sharma B, Bruner A, Barnett G, Fishman M. . Child and Adolescent Psychiatric Clinics of North America. July 2016, 25 (3): 473–87. PMC 4920977 . PMID 27338968. doi:10.1016/j.chc.2016.03.002.
1 2 3  . WHO.   [2019-04-06]. （原始内容存档于2019-04-21）.
1 2 3 4  GBD 2015 Mortality Causes of Death Collaborators. . Lancet. October 2016, 388 (10053): 1459–1544. PMC 5388903 . PMID 27733281. doi:10.1016/S0140-6736(16)31012-1.
↑  . 中华人民共和国国家卫生健康委员会.
↑  . National Institute on Drug Abuse. October 2015  [2018-07-16]. （原始内容存档于2018-07-14）.
1 2  Hughes, Evan. . New York Times. 2018-05-02  [2018-05-03]. （原始内容存档于2018-05-03）.
1 2 3 4 5  Santoro, T. N.; Santoro, J. D. . Cureus. 2018, 10 (12): e3733. PMC 6384031 . PMID 30800543. doi:10.7759/cureus.3733.
↑  Webster, LR. . Anesthesia and Analgesia. November 2017, 125 (5): 1741–1748. PMID 29049118. doi:10.1213/ANE.0000000000002496 .
1 2  Mohamadi A, Chan JJ, Lian J, Wright CL, Marin AM, Rodriguez EK, von Keudell A, Nazarian A. . The Journal of Bone and Joint Surgery. American Volume. August 2018, 100 (15): 1332–1340. PMID 30063596. S2CID 51891341. doi:10.2106/JBJS.17.01239.
1 2 3  GBD 2013 Mortality Causes of Death Collaborators. . Lancet. January 2015, 385 (9963): 117–71. PMC 4340604 . PMID 25530442. doi:10.1016/S0140-6736(14)61682-2.
↑   (PDF). CDC.   [2018-05-18]. （原始内容存档 (PDF)于2018-04-16）.
1 2 3 4  Volkow ND, Koob GF, McLellan AT. . The New England Journal of Medicine. January 2016, 374 (4): 363–71. PMC 6135257 . PMID 26816013. doi:10.1056/NEJMra1511480. Addiction: A term used to indicate the most severe, chronic stage of substance-use disorder, in which there is a substantial loss of self-control, as indicated by compulsive drug taking despite the desire to stop taking the drug. In the DSM-5, the term addiction is synonymous with the classification of severe substance-use disorder.
1 2 3 4  Nestler EJ. . Brain Research. August 2016, 1645: 71–4. PMC 4927417 . PMID 26740398. doi:10.1016/j.brainres.2015.12.039. Specifically, opiates in several CNS regions including NAc, and cocaine more selectively in NAc induce expression of certain adenylyl cyclase isoforms and PKA subunits via the transcription factor, CREB, and these transcriptional adaptations serve a homeostatic function to oppose drug action. In certain brain regions, such as locus coeruleus, these adaptations mediate aspects of physical opiate dependence and withdrawal, whereas in NAc they mediate reward tolerance and dependence that drives increased drug self-administration.
↑   5th. American Psychiatric Association. 2013: 547–549. ISBN 9780890425541.
1 2  Shah, Mansi; Huecker, Martin R., , StatPearls (StatPearls Publishing), 2019  [2019-10-21], PMID 30252268, （原始内容存档于2019-10-10）
1 2 3 4 5 6 7 8 9 10 11  Ries RK, Miller SC, Fiellin DA. . Lippincott Williams & Wilkins. 2009: 593–594. ISBN 9780781774772.
↑  Rahimi-Movaghar A, Gholami J, Amato L, Hoseinie L, Yousefi-Nooraie R, Amin-Esmaeili M. . The Cochrane Database of Systematic Reviews. June 2018, 2018 (6): CD007522. PMC 6513031 . PMID 29929212. doi:10.1002/14651858.CD007522.pub2.
↑  Treatment, Center for Substance Abuse. . www.ncbi.nlm.nih.gov. 2006  [2019-04-06]. （原始内容存档于2020-05-30） （英语）.
↑  Fentanyl. Image 4 of 17.  US DEA (Drug Enforcement Administration).
1 2  Kosten TR, Haile CN. Opioid-Related Disorders. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. eds. Harrison's Principles of Internal Medicine, 19e New York, NY: McGraw-Hill; 2014. http://accessmedicine.mhmedical.com/content.aspx?bookid=1130&sectionid=79757372 （页面存档备份，存于） Accessed 2017-03-09.
↑  Chen KW, Banducci AN, Guller L, Macatee RJ, Lavelle A, Daughters SB, Lejuez CW. . Drug and Alcohol Dependence. November 2011, 118 (2–3): 92–9. PMC 3188332 . PMID 21514751. doi:10.1016/j.drugalcdep.2011.03.003.
↑  Webster LR, Webster RM. . Pain Medicine. 2005, 6 (6): 432–42. PMID 16336480. doi:10.1111/j.1526-4637.2005.00072.x .
↑  Papaleontiou M, Henderson CR, Turner BJ, Moore AA, Olkhovskaya Y,Amanfo L, Reid MC. Outcomes associated with opioid use in thetreatment of chronic noncancer pain in older adults: a systematic reviewand meta-analysis. J Am Geriatr Soc 2010;58:1353–69.
1 2  Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioidtherapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manag 2008;35:214–28.
↑  Martell BA, O’Connor PG, Kerns RD, Becker WC, Morales KH, KostenTR, Fiellin DA. Systematic review: opioid treatment for chronic back pain:prevalence, efficacy, and association with addiction. Ann Intern Med2007;146:116–27
↑  Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. PAIN 2004;112:372–80
1 2  Goesling J., Dejonckheere M., Pierce J., et al Opioid cessation and chronic pain: Perspectives of former opioid users.   Pain. 2019;160(5):1131-1145. doi:10.1097/j.pain.0000000000001493
↑  Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES,Kroenke K, Bair MJ, Noorbaloochi S. Effect of opioid vs nonopioidmedications on pain-related function in patients with chronic back pain orhip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA2018;319:872–82.
↑  Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issueson opioids in chronic non-cancer pain: an epidemiological study. PAIN2006;125:172–9.
↑  Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, TurkDC. Opioids compared with placebo or other treatments for chronic lowback pain: an update of the Cochrane Review. Spine (Phila Pa 1976)2014;39:556–63.
↑   (PDF). World Health Organization. 2004  [2022-10-28]. ISBN 978-92-4-159115-7. （原始内容存档 (PDF)于2015-07-01）.
1 2 3 4  . WHO. 2004  [2016-08-28]. （原始内容存档于2010-06-14）. [需要更新]
↑  Longo, Dan L.; Volkow, Nora D.; Koob, George F.; McLellan, A. Thomas. . New England Journal of Medicine. 2016-01-28, 374 (4): 363–371. PMC 6135257 . PMID 26816013. doi:10.1056/NEJMra1511480.
↑  Hyman, SE. . The American Journal of Bioethics. January 2007, 7 (1): 8–11  [2022-10-28]. PMID 17366151. S2CID 347138. doi:10.1080/15265160601063969. （原始内容存档于2020-02-20）.
1 2 3 4 5 6 7  Nestler EJ. . Dialogues in Clinical Neuroscience. December 2013, 15 (4): 431–43. PMC 3898681 . PMID 24459410. doi:10.31887/DCNS.2013.15.4/enestler. Despite the importance of numerous psychosocial factors, at its core, drug addiction involves a biological process.
1 2 3  Malenka RC, Nestler EJ, Hyman SE. . Sydor A, Brown RY  (编).  2nd. New York: McGraw-Hill Medical. 2009: 364–375. ISBN 9780071481274.
1 2  . Mount Sinai School of Medicine. Department of Neuroscience.   [2015-02-09]. （原始内容存档于2019-05-10）.
1 2  Robison AJ, Nestler EJ. . Nature Reviews. Neuroscience. October 2011, 12 (11): 623–37. PMC 3272277 . PMID 21989194. doi:10.1038/nrn3111.
1 2  Olsen CM. . Neuropharmacology. December 2011, 61 (7): 1109–22. PMC 3139704 . PMID 21459101. doi:10.1016/j.neuropharm.2011.03.010.
1 2  Ruffle JK. . The American Journal of Drug and Alcohol Abuse. November 2014, 40 (6): 428–37. PMID 25083822. S2CID 19157711. doi:10.3109/00952990.2014.933840.
↑  Blum K, Werner T, Carnes S, Carnes P, Bowirrat A, Giordano J, Oscar-Berman M, Gold M. . Journal of Psychoactive Drugs. 2012, 44 (1): 38–55. PMC 4040958 . PMID 22641964. doi:10.1080/02791072.2012.662112.
1 2  Bourdy R, Barrot M. . Trends in Neurosciences. November 2012, 35 (11): 681–90. PMID 22824232. S2CID 43434322. doi:10.1016/j.tins.2012.06.007.
1 2  . KEGG. Kanehisa Laboratories. 2013-06-18  [2014-09-11]. （原始内容存档于2014-09-12）.
↑  Goldstein RZ, Volkow ND. . Nature Reviews. Neuroscience. October 2011, 12 (11): 652–69. PMC 3462342 . PMID 22011681. doi:10.1038/nrn3119.
↑  Schoenbum, Geoffrey; Shaham, Yavin. . Biol Psychiatry. February 2008, 63 (3): 256–262. PMC 2246020 . PMID 17719014. doi:10.1016/j.biopsych.2007.06.003.
↑  Ieong HF, Yuan Z. . Frontiers in Human Neuroscience. 2017-01-01, 11: 169. PMC 5382168 . PMID 28428748. doi:10.3389/fnhum.2017.00169  （英语）.
1 2   (PDF). American Psychiatric Association: 1–9.   [2017-03-27]. （原始内容 (PDF)存档于2017-11-26）.  |section=被忽略 (帮助)
↑  Vargas-Perez H, Ting-A Kee R, Walton CH, Hansen DM, Razavi R, Clarke L, Bufalino MR, Allison DW, Steffensen SC, van der Kooy D. . Science. June 2009, 324 (5935): 1732–4. Bibcode:2009Sci...324.1732V. PMC 2913611 . PMID 19478142. doi:10.1126/science.1168501.
↑  Laviolette SR, van der Kooy D. . The European Journal of Neuroscience. March 2001, 13 (5): 1009–15. PMID 11264674. S2CID 46694281. doi:10.1046/j.1460-9568.2001.01458.x.
↑  Hall FS, Drgonova J, Jain S, Uhl GR. . Pharmacology & Therapeutics. December 2013, 140 (3): 267–79. PMC 3797854 . PMID 23872493. doi:10.1016/j.pharmthera.2013.07.006.
↑  Bruehl S, Apkarian AV, Ballantyne JC, Berger A, Borsook D, Chen WG, Farrar JT, Haythornthwaite JA, Horn SD, Iadarola MJ, Inturrisi CE, Lao L, Mackey S, Mao J, Sawczuk A, Uhl GR, Witter J, Woolf CJ, Zubieta JK, Lin Y. . The Journal of Pain. February 2013, 14 (2): 103–13. PMC 3564046 . PMID 23374939. doi:10.1016/j.jpain.2012.10.016.
↑  . www.cdc.gov. 2018-08-31  [2018-11-03]. （原始内容存档于2018-11-02）.
↑  . CVS Health.   [2018-11-03]. （原始内容存档于2018-11-03）.
↑  . Walgreens.   [2018-11-03]. （原始内容存档于2018-11-03）.
↑  . www.cdc.gov. 2018-08-31  [2018-11-20]. （原始内容存档于2018-11-21）.
↑  . . 2017-10-23  [2017-11-02]. （原始内容存档于2017-11-07）.
↑   (PDF). U.S. Food and Drug Administration (FDA).   [2017-11-07]. （原始内容存档 (PDF)于2017-10-17）.
↑  . www.cdc.gov.   [9 March 2017]. （原始内容存档于2019-08-24）.
↑  Childs R.  (PDF). U.S. Food and Drug Administration (FDA). North Carolina Harm Reduction Coalition: 1–24. July 2015  [2017-11-02]. （原始内容存档 (PDF)于2017-08-30）.
↑  . NaloxoneInfo.org. Open Society Foundations.   [2017-11-02]. （原始内容存档于2017-11-07）.
↑  Schuckit MA. . The New England Journal of Medicine. July 2016, 375 (4): 357–68. PMID 27464203. doi:10.1056/NEJMra1604339 .
↑  Christie C, Baker C, Cooper R, Kennedy CP, Madras B, Bondi FA. The president’s commission on combating drug addiction and the opioid crisis. Washington, DC, US Government Printing Office, Nov. 2017;1.
↑  . CVS Health.   [2019-02-04]. （原始内容存档于2018-09-19） （英语）.
1 2  Morin K, Vojtesek F, Acharya S, Dabous J, Marsh D. Evidence of Increased Age and Sex Standardized Death Rates Among Individuals Who Accessed Opioid Agonist Treatment Before the Era of Synthetic Opioids in Ontario, Canada Cureus.  ;13(10). PMCID: PMC8608679.
↑  Hser YI, Hoffman V, Grella CE, Anglin MD: A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry.
2001, 58:503-8. 10.1001/archpsyc.58.5.503
↑  Horon IL, Singal P, Fowler DR, Sharfstein JM: Standard death certificates versus enhanced surveillance toidentify heroin overdose-related deaths. Am J Public Health. 2018, 108:777-81. 10.2105/AJPH.2018.304385
↑  Nicholls L, Bragaw L, Ruetsch C. . Journal of Managed Care Pharmacy. February 2010, 16 (1 Suppl B): S14–21  [2022-10-28]. PMID 20146550. doi:10.18553/jmcp.2010.16.S1-B.14 . （原始内容存档于2014-07-14）.
↑  Daubresse M, Gleason PP, Peng Y, Shah ND, Ritter ST, Alexander GC. . Pharmacoepidemiology and Drug Safety. April 2014, 23 (4): 419–27  [2022-10-28]. PMID 23881609. S2CID 25148439. doi:10.1002/pds.3487. （原始内容存档于2021-08-28）.
↑  Maxmen A. . Nature News. 2012. S2CID 180404159. doi:10.1038/nature.2012.10766.
↑  . MIGRATION AND HOME AFFAIRS. European Commission. 2017-03-14  [2022-10-28]. （原始内容存档于2019-01-10）.
1 2 3 4 5 6 7 8 9  Richard P. Mattick et al.: National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD): Report of Results and Recommendation
↑  Rees, John, Garcia, Gabriel.  Clinic Payment Options as a Barrier to Accessing Medication-assisted Treatment for Opioid Use in Albuquerque, New Mexico. ADDICT DISORD THEIR TREAT. 2019;18(4):246-248.  doi:10.1097/ADT.0000000000000175.
↑  Bruneau J, Ahamad K, Goyer MÈ, Poulin G, Selby P, Fischer B, Wild TC, Wood E. . CMAJ. March 2018, 190 (9): E247–E257. PMC 5837873 . PMID 29507156. doi:10.1503/cmaj.170958.
↑  Gowing L, Farrell M, Ali R, White JM. . The Cochrane Database of Systematic Reviews. May 2016, (5): CD002024. PMC 7081129 . PMID 27140827. doi:10.1002/14651858.CD002024.pub5.
↑  Michel et al.: Substitution treatment for opioid addicts in Germany （页面存档备份，存于）, Harm Reduct J. 2007; 4: 5.
↑  Bonhomme J, Shim RS, Gooden R, Tyus D, Rust G. . Journal of the National Medical Association. July 2012, 104 (7–8): 342–50. PMC 4039205 . PMID 23092049. doi:10.1016/S0027-9684(15)30175-9.
↑  Orman JS, Keating GM. . Drugs. 2009, 69 (5): 577–607. PMID 19368419. S2CID 209147406. doi:10.2165/00003495-200969050-00006.
1 2  . Substance Abuse and Mental Health Services Administration.   [2018-11-20]. []
↑  Gastfriend DR. . Annals of the New York Academy of Sciences. January 2011, 1216 (1): 144–66. Bibcode:2011NYASA1216..144G. PMID 21272018. S2CID 45133931. doi:10.1111/j.1749-6632.2010.05900.x.
↑   (PDF). DEA.   [2022-10-28]. （原始内容存档 (PDF)于2020-05-15）.
↑  . U.S. Food and Drug Administration (FDA). 2002-10-08  [2014-11-01]. （原始内容存档于2017-07-22）.
↑  Dalsbø, T. K.; Steiro, A. K.; Hammerstrøm, K. T.; Smedslund, G. . June 2010. PMID 29320074.
↑  Ferri M, Davoli M, Perucci CA. . The Cochrane Database of Systematic Reviews. December 2011, (12): CD003410. PMC 7017638 . PMID 22161378. S2CID 6772720. doi:10.1002/14651858.CD003410.pub4.
↑  Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. . Lancet. October 2001, 358 (9291): 1417–23. PMID 11705488. S2CID 24542893. doi:10.1016/S0140-6736(01)06529-1.
↑  .   [2016-03-04]. （原始内容存档于2016-03-16）.
↑  Robertson JR, Raab GM, Bruce M, McKenzie JS, Storkey HR, Salter A. . Addiction. December 2006, 101 (12): 1752–9. PMID 17156174. doi:10.1111/j.1360-0443.2006.01603.x.
↑  . Pubchem.   [2022-10-28]. （原始内容存档于2018-11-21）.
↑  . online.lexi.com.   [2018-11-02]. （原始内容存档于2018-11-21）.
↑  Carney, Tara; Van Hout, Marie Claire; Norman, Ian; Dada, Siphokazi; Siegfried, Nandi; Parry, Charles Dh. . The Cochrane Database of Systematic Reviews. 18 February 2020, 2: CD012254. ISSN 1469-493X. PMC 7027221 . PMID 32068247. doi:10.1002/14651858.CD012254.pub2.
↑  Ferri M, Minozzi S, Bo A, Amato L. . The Cochrane Database of Systematic Reviews. June 2013, (6): CD009879. PMID 23740540. doi:10.1002/14651858.CD009879.pub2.
↑  . （原始内容存档于13 March 2016）.
1 2   (PDF). Alkermes Inc. March 2021  [1 February 2022]. （原始内容存档 (PDF)于2022-10-22）.
↑  Skolnick P. . Annual Review of Pharmacology and Toxicology. January 2018, 58 (1): 143–159. PMID 28968188. doi:10.1146/annurev-pharmtox-010617-052534 .
↑  Sullivan MA, Garawi F, Bisaga A, Comer SD, Carpenter K, Raby WN, Anen SJ, Brooks AC, Jiang H, Akerele E, Nunes EV. . Drug and Alcohol Dependence. December 2007, 91 (2–3): 289–92. PMC 4153601 . PMID 17681716. doi:10.1016/j.drugalcdep.2007.06.013.
↑  Center for Substance Abuse Treatment. . Substance Abuse and Mental Health Services Administration (US). 2009  [2022-10-28]. （原始内容存档于2017-02-19）.
↑  Beck JS.  Second. New York. 2011-08-18: 19–20. ISBN 9781609185046. OCLC 698332858.
↑  Huibers MJ, Beurskens AJ, Bleijenberg G, van Schayck CP. . The Cochrane Database of Systematic Reviews. July 2007, (3): CD003494. PMC 7003673 . PMID 17636726. doi:10.1002/14651858.CD003494.pub2. hdl:2066/52984 .
↑  Longo, Dan L.; Schuckit, Marc A. . New England Journal of Medicine. 2016-07-28, 375 (4): 357–368. PMID 27464203. doi:10.1056/NEJMra1604339 .
↑  VASILAKI, EIRINI I.; HOSIER, STEVEN G.; COX, W. MILES. . Alcohol and Alcoholism. May 2006, 41 (3): 328–335. PMID 16547122. doi:10.1093/alcalc/agl016 .
↑  . www.uptodate.com.   [2017-11-02]. （原始内容存档于2017-11-08）.
↑  Melemis SM. . The Yale Journal of Biology and Medicine. September 2015, 88 (3): 325–32. PMC 4553654 . PMID 26339217.
↑  . www.na.org.   [2018-11-20]. （原始内容存档于2018-11-19）.
↑  Sussman S. . Evaluation & the Health Professions. March 2010, 33 (1): 26–55. PMC 4181564 . PMID 20164105. doi:10.1177/0163278709356186.
↑  . American Addiction Centers.   [2017-10-24]. （原始内容存档于2017-10-11）.
↑  .   [2022-10-28]. （原始内容存档于2022-12-19）.
↑  .   [2022-10-28]. （原始内容存档于2022-10-23）.
↑  . Fierce Biotec. 2020-11-06  [2022-02-01]. （原始内容存档于2022-10-22）.
↑  Opioid Data Analysis and Resources. Drug Overdose. CDC Injury Center. Centers for Disease Control and Prevention. Click on "Rising Rates" tab for a graph. See data table below the graph.
↑  American Society of Addiction Medicine.  (PDF).   [2022-10-28]. （原始内容存档 (PDF)于2018-01-25）.
↑   (PDF). Hyattsville, MD.: CDC, National Center for Health Statistics. 2017: 4  [2022-10-28]. （原始内容存档 (PDF)于2017-09-29）.
1 2  (DCD), Digital Communications Division. . HHS.gov. 2018-05-08  [2018-11-02]. （原始内容存档于2018-11-03）.
↑   (PDF). U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES.   [2018-11-18]. （原始内容存档 (PDF)于2018-11-20）.
1 2  . Center for Disease Control and Prevention.   [2016-09-12]. （原始内容存档于2019-08-24）.
1 2  Paulozzi L.  (PDF). U.S. Food and Drug Administration (FDA). Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control Centers for Disease Control and Prevention. 2012-04-12  [2016-09-12]. （原始内容存档 (PDF)于2017-02-15）.
↑   (PDF). American Society of Addiction Medicine.   [2016-09-12]. （原始内容存档 (PDF)于2018-01-25）.
1 2  . PBS.   [2016-09-12]. （原始内容存档于2016-09-12）.
1 2  Han B, Polydorou S, Ferris R, Blaum CS, Ross S, McNeely J. . Substance Use & Misuse. 2015-11-10, 50 (13): 1660–7. PMID 26584180. S2CID 5520930. doi:10.3109/10826084.2015.1027929.
↑  . MAP Health Management. 2015  [2016-09-12]. （原始内容存档于2020-02-29）.
↑  . Substance Abuse and Mental Health Services Administration. 2016-02-23  [2016-09-12]. （原始内容存档于2016-09-12）.
↑  DeVencentis P. . USA Today. 2017-07-24  [2022-10-28]. （原始内容存档于2020-11-09）.
↑   Note, Recent Case: Massachusetts Supreme Judicial Court Holds Drug-Free Probation Requirement Enforceable for Defendant with Substance Use Disorder, 132 Harv. L. Rev. 2074 (2019).
↑  Commonwealth v. Eldred, 101 N.E.3d 911 (Mass. 2018).
↑  .   [2022-10-28]. （原始内容存档于2022-10-22）.
↑  . 2021-10-07  [2022-10-28]. （原始内容存档于2022-11-28）.
↑  . 2021-11-04  [2022-10-28]. （原始内容存档于2021-11-25）.
1 2 3 4  Overdose Death Rates （页面存档备份，存于）. By National Institute on Drug Abuse (NIDA).
↑  James W. Kalat, Biological Psychology. Cengage Learning. Page 81.
↑  EMEA 2001-04-19 EMEA Public Statement on the Recommendation to Suspend the Marketing Authorisation for Orlaam (Levacetylmethadol) in the European Union （页面存档备份，存于）
↑  . American AddictionCenters ProjectKnow.com. 2021-08-20  [2022-02-03]. （原始内容存档于2022-11-29）. Orlaam was discontinued in 2003 in the United States, and it is not prescribed here anymore.